NM26-2198 is a bispecific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis, or AD. NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration.

ND081 is a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD). The program is partnered with Kaken Pharmaceutical under a Collaboration and Option Agreement. Kaken has an option to acquire commercial rights to ND081 for certain key Asian territories in exchange for funding preclinical and clinical development up to Phase 2a proof of concept.

NM09 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease (IBD), a chronic inflammation of the digestive tract that primarily includes ulcerative colitis and Crohn’s disease. Anti-TNF therapy has been shown to reduce the need for hospitalization and surgical interventions in IBD and improve quality of life. Numab’s highly stable antibody fragment NM009 has best-in-class potency and is licensed to Mage Biologics for the development and commercialization of innovative formulations.

ND059 is a collaboration project partnered with Boehringer Ingelheim to develop a candidate against geographic atrophy, a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

Numab is developing multiple proprietary inflammation programs utilizing our versatile, multi-specific MATCH™ platform. We are combining antagonism of multiple  disease-driving pathways to create innovative, multi-functional drug candidates. With these rationally designed drug candidates we seek to exceed the reaches of current standard of care medication in inflammatory diseases to provide much needed improvement in the quality of life for patients.

NM32-2668 is a tri-specific anti-ROR1/CD3/HSA antibody based on our scMATCH3 format. NM32-2668 induces T cell-mediated lysis of tumors expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). Binding to human serum albumin (HSA) prolongs the half-life of the molecule in circulation and supports a convenient dosing scheme. ROR1 is overexpressed on a variety of difficult to treat tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), triple-negative breast cancer (TNBC), lung cancer, and ovarian cancer. ROR1-expressing hematologic and solid tumors display a high potential for self-renewal, increased survival, and migration, and are associated with poor outcomes.

ND037 refers to an undisclosed number of discovery projects partnered with Eisai, aimed at the identification of novel multi-specific antibody fragment-based molecules for immuno-oncology.

ND038 is a collaboration project partnered with Eisai, with the goal of leveraging Numab’s multi-specific technology to generate a cancer therapeutic that provides superior efficacy and safety compared to benchmark immunotherapies.

NM23 is a collaboration project partnered with Ono Pharmaceutical, (the originator of the anti-PD1 antibody Nivolumab/Opdivo®) aimed at the discovery of a multi-specific antibody fragment-based molecule for immuno-oncology.

ND039 is a collaboration project partnered with Ono Pharmaceutical, (the originator of the anti-PD1 antibody Nivolumab/Opdivo®) aimed at the discovery of a multi-specific antibody fragment-based molecule for immuno-oncology.

ND047 is a collaboration project partnered with Boehringer Ingelheim with the goal to develop a T-cell engager for the treatment of gastrointestinal cancer based on Numab’s multi-specific antibody platform.

NM49 is a multi-specific antibody designed to activate anti-tumor immune responses, and in particular tumor associated macrophage phagocytosis. The program is partnered with Ono Pharmaceutical under a research and license option agreement. Numab has an option to co-develop NM49 with profit split arrangement in the United States.

Numab is developing multiple proprietary immuno-oncology programs utilizing our versatile, multi-specific MATCH™ platform. We are combining immune effector functions, immune-checkpoint antagonism, and cancer-specific targeting to create innovative, multi-functional drug candidates. These drug candidates are rationally designed to activate key components of the innate and adaptive immune system to bring significant improvement to the lives of cancer patients.